How Novartis’s Tasigna Is Looking Now



Tasigna revenue trends

In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which was ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter). Sales growth in the US and emerging markets primarily attributed to the revenue growth of Novartis in 3Q17.

ENTESTfreedom and ENTESTop trials

In June 2017, Novartis presented the results from the additional analysis of its phase-3 ENESTfreedom and ENESTop trials. The phase-3 ENESTfreedom and ENESTop trial demonstrated that around half of adult individuals with Philadelphia chromosome-positive chronic myeloid leukemia (or CML) in the chronic phase who discontinued Tasigna remained in treatment-free remission (or TFR) for approximately two years after stopping therapy.

The ENTESTfreedom trial evaluated the potential of discontinuation of Tasigna therapy in eligible candidates with Philadelphia chromosome-positive chronic myeloid leukemia (or CML) who achieved a sustained deep molecular response (or DMR) after a minimum of three years of first-line Tasigna therapy.

In the marketplace, Novartis Tasigna competes with Bristol-Myers Squibb’s (BMY) Sprycel, Pfizer’s (PFE) Bosulif, and Takeda Pharmaceuticals’ (TKPYY) Iclusig. In 3Q17, Sprycel reported revenues of ~$509 million. The Vanguard International High Dividend Yield ETF (VYMI) has ~1.18% of its total portfolio holdings in NVS.

More From Market Realist